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Several lines of evidence support a “dopaminergic hypothesis” in the pathophysiology of Gilles de la
Tourette syndrome (TS). The aim of this study was to investigate for the ﬁrst time epigenetic changes in
DNA methylation in different dopamine genes in adult patients with TS. We included 51 well charac-
terized adult patients with TS (41 males, 10 females, mean age ¼ 35 ± 12.6 years, range, 18e71 years) and
compared results with data from a group of 51 sex- and age-matched healthy controls. Bisulﬁte
sequencing was used to measure peripheral DNA methylation of the dopamine transporter (DAT), the
dopamine D2 receptor (DRD2), and the catechol-O-methyltransferase (COMT) genes. Compared to
healthy controls, patients with TS showed signiﬁcantly elevated methylation level of the DRD2 gene that
positively correlated with tic severity. In contrast, DAT methylation was lower in more severely affected
patients. Our results provide evidence for a role of altered epigenetic regulation of dopaminergic genes in
the pathophysiology of TS. While DRD2 hypermethylation seems to be directly related to the neurobi-
ology of TS that may lead to dopaminergic dysfunction resulting in enhanced thalamo-cortical move-
ment-stimulating activity, DAT hypomethylation might reﬂect a secondary mechanism in order to
compensate for increased dopaminergic signal transduction due to DRD2 hypermethylation. In addition,
it can be speculated that spontaneous ﬂuctuations of tics may be caused by short-term alterations of
methylation levels of dopaminergic genes resulting in dynamic changes of tonic/phasic dopaminergic
signaling in the striatum and thalamo-cortical output pathways.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gilles de la Tourette syndrome (TS) is a childhood-onset chronic
neuro-psychiatric disorder characterized by the combination of
multiple motor and at least one vocal tic. The majority of patients,
in addition, suffers from psychiatric comorbidities such as attention
deﬁcit hyperactivity disorder (ADHD), obsessive compulsive dis-
order (OCD), self-injurious behavior, depression, and anxiety dis-
order. The underlying cause of the disease is still unknown. Several
studies provided evidence for an involvement of cortico-striato-
thalamo-cortical (CSTC) circuitry. Mink (2001) suggested an aber-
rant activity in a particular set of neurons in the striatum (caudate
nucleus and putamen) leading consequentially e via increasedsychiatry and Psychotherapy,
25, Hannover, Germany.
r.de (K.R. Müller-Vahl).
Ltd. This is an open access article uinhibition of the globus pallidus internus and the substantia nigra
pars reticulata and reduced inhibition of the thalamus - to an
excitation of cortical neurons involved in movements. In line with
this hypothesis, most structural neuroimaging studies have shown
abnormalities of the basal ganglia nuclei, most consistently reduced
volume of the caudate nucleus (Makki et al., 2008; Müller-Vahl
et al., 2009; Peterson et al., 1993). In addition, a negative correla-
tion between caudate volume in childhood and tic severity later in
life could be demonstrated (Bloch et al., 2005). It is thought that
atypical neurochemical transmission within the basal ganglia leads
to the aberrant integrative interplay of CSTC circuitry (Mink, 2001;
Singer, 2013). Different neurotransmitter systems have been sug-
gested to be involved in the pathogenesis of TS including the
dopaminergic, serotonergic, glutamatergic, gamma-amino butyric
acid-(GABA)ergic, histaminergic, and endocannabinoid systems
(Martino and Leckman, 2013).
The strongest evidence, however, supports a “dopaminergicnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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assumption is not only supported by the well-known beneﬁcial
effects of dopamine receptor blocking drugs (antipsychotics) on tics
(Roessner et al., 2011), but also several other ﬁndings including
alterations in both presynaptic dopamine transporters (DAT) and
postsynaptic dopamine D2 receptors (DRD2) in striatal and extra-
striatal regions (Gilbert et al., 2006; Minzer et al., 2004; Müller-
Vahl et al., 2000; Serra-Mestres et al., 2004; Steeves et al., 2010;
Turjanski et al., 1994; Wong et al., 1997; Yoon et al., 2007a).
Accordingly, different “dopaminergic hypotheses” have been pro-
posed in TS due to either supersensitive postsynaptic striatal re-
ceptors, dopamine hyperinnervation within the striatum,
presynaptic abnormality in dopa carboxylase, or elevated intra-
synaptic dopamine release as a result of an imbalance between
tonic and phasic levels. Of these various proposed changes within
the dopaminergic system, most evidence supports an alteration of
the tonic-phasic dopamine release system (Singer, 2013). Based on
the detection of increased presynaptic dopamine uptake sites in
both the striatum (Singer et al., 1991) and the frontal cortex (Minzer
et al., 2004) and increased striatal DAT binding (Malison et al., 1995;
Müller-Vahl et al., 2000; Serra-Mestres et al., 2004), a reduction in
extrasynaptic tonic (homeostatic) dopamine levels has been sug-
gested. It is believed that tonic dopamine is regulated by presyn-
aptic D2 and D3 autoreceptors (Rice et al., 2011). In addition, the
observation of an increased release of dopamine in the striatum
following amphetamine stimulation (Singer et al., 2002; Wong
et al., 2008) - as a measure of synaptically focused, phasic (spike-
dependent) dopamine - suggests abnormalities in the transient
phasic release of dopamine into striatal regions. In summary, it is
believed that in TS an abnormal interaction between tonic and
phasic dopaminergic signaling results in altered modulation of
CSTC circuitry (Singer, 2013).
Based on twin and family studies it is generally believed that
there is a genetic etiology in TS. It can be assumed that multiple
variations in multiple genes are likely to be carrying the risk for TS.
However, the only available genome-wide association study
(GWAS) of TS failed to demonstrate genome-wide signiﬁcant loci
(Scharf et al., 2013). A recently performed large multicenter study
failed to replicate previously implicated individual single nucleo-
tide polymorphisms (SNPs) and candidate genes in TS (unpublished
data). During the last years, a large number of neurotransmitter
related candidate gene association studies has been performed that
included - besides several other genes involved in neuro-
developmental, neuroendocrine, and immunological function -
various dopamine receptor genes including the DRD2, dopamine
D3 receptor (DRD3), dopamine D4 receptor (DRD4) gene as well as
the DAT gene and the dopamine catabolizing enzyme catechol-O-
methyltransferase (COMT) gene. However, all these studies failed
to demonstrate signiﬁcant reproducible ﬁndings (for review see
Paschou, 2013).
Most of the available evidence points to the hypothesis that TS is
related to an interplay of both genetic and epigenetic factors. Until
today, several different environmental factors have been suggested
to play a crucial role in the onset and natural course of the disorder
including perinatal risk factors, hormonal factors, psychosocial
stress, immune mechanisms, and infections (in particular group A
streptococcal (GAS) infections). For example, there is evidence that
older paternal age, maternal smoking during pregnancy, severe
maternal psychosocial stress during pregnancy, delivery compli-
cations, low Apgar score, and low birth weight contribute to the
development of TS and are associated with increased tic severity,
respectively (Burd et al., 1999; Hyde et al., 1992; Leckman et al.,
1987; Mathews et al., 2006). Although there is little doubt that
environmental factors are involved in the etiology of TS, no single
factor could yet be identiﬁed (for review see Hoekstra et al., 2013).During recent years, it became clear that gene expression can be
affected not only by DNA sequences, but also epigenetic modiﬁca-
tions. Since these epigenetic changes can be induced by environ-
mental factors, a major role of epigenetic variations has been
suggested in the etiology of neurodevelopmental disorders via
alteration of neural gene function (Kubota et al., 2014). There are
several lines of evidence suggesting that DNA methylations at
cytosine-phosphate-guanine (CpG) dinucleotides are involved in
several complex neuro-psychiatric disorders. Only recently, the
ﬁrst epigenome-wide association study has been published
including DNA methylation data consisted of 411,169 autosomal
methylation sites in 1678 individuals (188 cases and 1490 controls)
(Zilh~ao et al., 2015). Although no probes reached genome-wide
signiﬁcance, some of the top ranking probes mapped to genes
that have been previously described in association with neuro-
psychiatric disorders (including GABBRI, BLM, and ADAM10).
The aim of this study was to investigate for the ﬁrst time
epigenetic differences in DNA methylation in different dopami-
nergic genes including DRD2, DAT, and COMT in a group of adult
patients with TS.
2. Material and methods
2.1. Patients
In this study, 51 adult patients with TS (18 years) were
included between 5/2012 and 3/2013. Patients were recruited from
the Tourette outpatient department at the Hannover Medical
School and the German Tourette advocacy group (Tourette Gesell-
schaft Deutschland e.V.). In all patients, the diagnoses of TS and
psychiatric comorbidities according to DSM-IV-TR were conﬁrmed
by one of the authors (KMV), who is a neurologist and adult psy-
chiatrist and a well experienced TS expert. The following exclusion
criteriawere deﬁned: (1) age< 18 years, (2) secondary tic disorders,
and (3) additional diagnosis of psychosis, epilepsy, drug and alcohol
dependency, clear mental retardation, regular cannabis use (>once
a week for at least 6 months) at present time and/or during the last
5 years. Common psychiatric comorbidities of TS (such as ADHD,
OCD, depression, anxiety), other behavioral problems as well as
medication for tics and comorbidities were no exclusion criteria.
For clinical characterization of the patients' group we used
several different well established assessments: (1) Yale Global Tic
Severity Scale (YGTSS) (Leckman et al., 1989) including YGTSS e
total tic score (TTS) and YGTSS e global score (GS) (¼YGTSS-
TTS þ impairment score), (2) Premonitory Urge for Tics Scale
(PUTS) (Woods et al., 2005), (3) Yale-Brown Obsessive Compulsive
Scale (Y-BOCS) (Goodman et al., 1989), (4) Conners' Adult ADHD
Rating Scale (CAARS) (Conners et al., 1999), (5) DSM-IV symptom
list for ADHD (APA e American Psychiatric Association, 2000), (6)
Wender Utah Rating Scale short version (WURS-K) (Retz-Junginger
et al., 2002), (7) Beck Depressions Inventory (BDI) (Beck et al., 1961),
(8) State-Trait-Anxiety Inventory (STAI) (Laux et al., 1981), (9) Brief
Symptom Inventory (BSI) (global severity index (GSI)) (Franke,
2000), (10) Gilles de la Tourette Syndrome e Quality of Life Scale
(GTS-QOL) (Cavanna et al., 2008).
For further analyses (see below), we formed three groups of
patients according to tic severity (as assessed by YGTSS-TTS):
“mild” TS (YGTSS-TTS14), “moderate” TS (YGTSS-TTS ¼ 15e34),
and “severe” TS (YGTSS-TTS35). Used YGTSS-TTS cut-off values
follow general recommendations for treatment: a score 15 is
suggested to indicate clinically signiﬁcant tics, while a score 35
seems to be adequate to display tics as ‘‘severe’’ (Müller-Vahl et al.,
2011; Wilhelm et al., 2012). To investigate the inﬂuence of comor-
bidities, in addition, we made not only the diagnoses of comorbid
OCD, ADHD, and depression (based on clinical interview and
Table 2
Cycle conditions.
COMT
1. 95 C 15min
2. 95 C 30sec
3. 59 C 1min 30sec
4. 72 C 2min 30sec 5
5. 95 C 30sec
6. 59 C 30sec
7. 72 C 45sec 30
8. 72 C 4min
DAT
1. 95 C 15min
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depending on the number of psychiatric comorbidities (Freeman
et al., 2000) (including OCD, depression, and ADHD, ranging from
0 to 3).
All subjects gave written informed consent before entering the
study. The study was approved by the ethics committee of the
Hannover Medical School. For this study we did not recruit a group
of healthy controls, but used data from healthy volunteers already
available in the Molecular Neuroscience Laboratory of the Clinic of
Psychiatry, Socialpsychiatry and Psychotherapy at the Hannover
Medical School.2. 95 C 30sec
3. 56 C 1min 30sec
4. 72 C 2min 30sec 5
5. 95 C 30sec
6. 56 C 30sec
7. 72 C 45sec 30
8. 72 C 4min
DRD2 (Nested-Touchdown-PCR)
1. 95 C 15min
2. 97 C 1min
3. 95 C 30sec
4. 62 C 45sec 1C/cycle
5. 68 C 1min 15
6. 95 C 30sec
7. 47 C 45sec
8. 65 C 1min 20
9. 65 C 5min2.2. DNA Methylation
Fasting blood samples for DNA extraction were drawn at the
beginning of the study visit. Genomic DNA was extracted from
whole frozen EDTA-blood with the NucleoMag® 96 Blood Kit
(Macherey Nagel, Dueren, Germany) according to the manufac-
turer's protocol. Afterwards, 500 ng of genomic DNAwere modiﬁed
by sodium-bisulﬁte using the EpiTect® Bisulﬁte Kit (QIAGEN AG,
Hilden, Germany). Sodium-bisulﬁte deaminates cytosines in CpG
dinuleotides to uracils, whereas methylated cytosines are protected
from alteration.
Primers were designed to amplify a region upstream and within
exon 1 of DRD2, DAT and COMT gene. PCR was conducted using
HotStarTaq Master Mix Kit (Qiagen, Hilden, Germany). Cycle con-
ditions, primer sequences as well as fragment sizes and chromo-
somal positions are listed in Tables 1 and 2. Subsequently each PCR
product was visualized on a standard 2.0% agarose gel, followed by
puriﬁcation using Agencourt AMPure XP beads (Beckman Coulter
GmbH, Krefeld, Germany). Sequencing was performed using a
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA, USA) according to themanufacturer's instructions. A
maximum concentration of 30 ng puriﬁed PCR product was applied
for the extension reaction. After dye-terminator removal with
Agencourt CleanSEQ System (Beckman Coulter), the products were
analyzed on an Applied Biosystems® 3500xL DNA Analyzer
(Applied Biosystems).
The obtained sequences were analyzed using the ESME software
package that determines the DNA methylation levels from the
sequence trace ﬁles. ESME performs quality control, normalizes the
signals, corrects for incomplete bisulﬁte conversion, and aligns
generated bisulﬁte sequence and reference sequence to compare C
toT values (forward sequence) and G to A values (reverse sequence)
peaks at CpG-sites (Lewin et al., 2004).Table 1
Primer sequences, fragment sizes and chromosomal positions.
PCR Primer Sequence Tm (C) Position in r
to Exon 1 (b
1 COMT-MB-F1-495 TTAGTTTTTTTATTTGGGAAGGG 56
COMT-MB-R1-497 CCAATATTCCACCCTAAATCTA 56 111 to þ36
COMT-R-Seq-66 TCCACCCTAAATCTAAAAACCCC 61
1 DRD2-Bis-F1-540 GTAATTTTTGGTTTTTGAGTT 50
DRD2-Bis-R1-542 CACAAACTTCTAATCCTAACCT 56 428 to þ29
2 DRD2-Bis-F2-541 GAGGAGGTATAGTTTTTTTGGT 58
DRD2-Bis-R2-544 CTACTTAAAACTTCCAACTCCC 58 235 to þ16
1 DAT-F-501 AGGGGAGTGGTGGTGTG 57
DAT-R-503 AAATCCCCTAAACCTAATCCC 57 1157 to 6
DAT-R-Seq-519 CCTAAAAAAACCATTTCCC 512.3. Statistical analysis
Bisulﬁte sequencing yieldedmethylation values of 60 single CpG
sites in the DRD2 gene, 36 in the DAT gene, and 51 in the COMT
gene. We performed initial quality checks to exclude potentially
unreliable measurements: (i) All obtained sequences were
screened for sequencing quality using ABI sequence scanner
(Applied Biosystems). Samples with a QV-value below 20 were
measured again. For the ﬁnal analysis, all sequences were above the
QV threshold of 20. (ii) Individual CpG sites with more than 20%
missing values were excluded from the analysis, leaving 53 CpG
sites in DRD2, 35 in DAT and 50 in COMT. (iii) Participants with
more than 20%missing values were excluded from the analysis (per
gene: DRD2: twoTS patients (IDs 2; 34), two control subjects (IDs 3;
30); DAT and COMT: all subjects included). (iv) Only CpG sites with
an inter-individual variance above 0.01 were included into the
analysis (DRD2: 26 CpG sites, DAT: 6 CpG sites). In the COMT gene
no CpG site passed this criterion (furthermore, standard deviationelation
p)
Product
size (bp)
Location on Chromosome (GRCh38.p2 Primary Assembly)
8 480 >gij568815576jrefjNC_000022.11j:19941496e19941975
Homo sapiens chromosome 22
8 726 >gij568815587jrefjNC_000011.10j:113474981e113475706
Homo sapiens chromosome 11
3 399 >gij568815587jrefjNC_000011.10j:113475116e113475530
Homo sapiens chromosome 11
23 534 >gij568815593jrefjNC_000005.10j:1446052e1446585
Homo sapiens chromosome 5
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not further analyzed.
In order to achieve normal distribution, methylation values
were ln-transformed (ln_methylation ¼ (ln(1 þ methylation)). All
linear mixedmodels included participants as random effects. In the
ﬁrst step our models contained methylation (or the transformed
methylation variables respectively) as dependent variable and
diagnosis, age and gender as predictors and CpG position as
repeated measure. In subsequent models, medication use (antide-
pressants, antipsychotics, others) was added as potential covariate.
In the last models, only patients were analyzed and severity of TS (3
groups based on YGTSS-TSS scores: YGTSS-TTS14 (“mild” TS,
n ¼ 7), YGTSS-TTS ¼ 15e34 (“moderate” TS, n ¼ 31), and YGTSS-
TTS35 (“severe” TS, n¼ 13)) and presence or absence of comorbid
OCD, ADHD, and depression were included as possible predictors.
F-statistics of ﬁxed effects were used to assess the value of single
predictors in the best ﬁtting models. To avoid overﬁtting, we did
not include comorbidities into the analyses. In all models, a scaled
identity covariance structurewas applied. For statistical analysis we
used Statistical Package for the Social Sciences (SPSS) for Windows
Version 22.3. Results
3.1. Clinical characteristics of patients
We included 51 patients (41 males, 10 females, mean
age ¼ 35 ± 12.6 years, range, 18e71 years). Of these, 31 patients
received medical treatment for tics and/or comorbidities (multiple
answers possible): n ¼ 22 antipsychotic drugs, n ¼ 18 antidepres-
sants, n¼ 3methylphenidate, n¼ 1 cannabinoid-based medication
(tetrahydrocannabinol), and n ¼ 1 dopamine agonist. Fourteen
patients were treated with more than one drug, 17 patients
received monotherapy with one drug, and 20 patients were drug-
free. Six patients were treated with deep brain stimulation (DBS)
(2 of these patients were drug-free). Clinical characteristics are
summarized in Table 3. According to both clinical interview and
standardized assessments, the diagnosis of comorbid OCD was
made in 23 patients, of ADHD in 19 patients, and of depression in 14
patients. In addition, we calculated a comorbidity score depending
on the number of comorbid disorders and found no comorbidity in
16 patients (¼TS only), one comorbidity in 7 patients, two comor-
bidities in 12 patients, and three comorbidities in 3 patients. Due to
missing data, in 13 patients no comorbidity score could be
calculated.
Results were compared with data from a sex- and age matched
control group (n ¼ 51, 15 females, 35 males, mean age ¼ 35 ± 11.9Table 3
Clinical characteristics of patients with TS.
Assessments Na Mean SD Range
YGTSS-TTS 51 26.45 10.94 0-48 (0e50)
YGTSS-GS 51 56.27 22.47 0-98 (0e100)
PUTS 42 24.74 6.98 10-35 (9e36)
Y-BOCS 51 12.82 9.96 0-33 (0e40)
CAARS DSM-IV-Total 31 52.00 15.16 34e90
CAARS ADHS Index 31 50.65 11.62 37e81
ADHD DSM-IV symptom list 43 7.00 4.73 0-15 (0e18)
WURS-k 40 30.40 16.23 6-63 (0e84)
BDI 38 13.68 11.28 1-40 (0e63)
STAI: X1 48 44.77 13.36 22-72 (20e80)
STAI: X2 47 47.96 11.29 26-72 (20e80)
BSI (GSI) 47 65.53 12.84 35-80 (20e80)
GTS-QOL 46 35.15 21.55 2,78e75 (0e100)
a The variations in sample size are due to missing data.years, range, 18-17 years). All control subjects were randomly
selected and were negative for any axis 1 diagnosis according to
ICD-10 and DSM-IV, other medical and neurological disorders, and
received no psychopharmacological therapy.3.2. DNA-Methylation
3.2.1. DRD2 gene
3.2.1.1. Comparison of patients and controls. The best ﬁtting model
including patients and controls contained the predictors age,
gender, diagnosis of TS, antipsychotic medication, CpG position,
and CpG*diagnosis interaction. In this model, we found signiﬁcant
ﬁxed effects of age (F(1,2450) ¼ 18.34; P < 0.001; estimate: 0.00076;
standard error: 0.000178), CpG position (F(25,2450) ¼ 4.94;
P < 0.001), and diagnosis of GTS (F(1, 2450) ¼ 13.16; P < 0.001), with
methylation increasing with age and signiﬁcantly elevated
methylation levels in patients (patients: 0.081 (0.03) vs. controls:
0.053 (0.02), see Fig. 1). While antipsychotic medication only
showed a trend towards an association (F(1;2450) ¼ 3.28; P ¼ 0.070),
other medications (including antidepressants) had no inﬂuence.
Comorbidities also had no inﬂuence on DRD2 methylation.3.2.1.2. Inﬂuence of tic severity. The best ﬁtting model contained
the predictors age, gender, YGTSS-TTS, and antipsychotic medica-
tion, when analyzing patients only. Neither kind nor number
(¼comorbidity score) of comorbid psychiatric disorders showed
any effect and, therefore, were not included in the ﬁnal model. In
this model, age (F(1,1220) ¼ 5.18; P ¼ 0.023), CpG position
(F(25,1220) ¼ 3.17; P < 0.001) and severity of tics according to YGTSS-
TTS (F(2,1220) ¼ 6.20; P ¼ 0.002) had signiﬁcant effects on DRD2
methylation: DRD2 methylationwas higher in older patients and in
those with more severe tics (compare Fig. 2).3.2.2. DAT gene
Analyzing patients and controls together, again the model
containing age, gender, CpG position, diagnosis of TS, antipsychotic
medication, and CpG*diagnosis interaction ﬁtted the data best. In
this model, only age had a signiﬁcant impact on DAT methylation
(F(1,596) ¼ 11.45; P ¼ 0.001; estimate: 0.00099; standard
error¼ 0.00029), while we did not observe any difference between
patients and controls (F(1,596) ¼ 0.663; P ¼ 0.42).
However, in the analysis of patients only including the pre-
dictors age, gender, YGTSS-TTS, and antipsychotic medication, we
found a signiﬁcant effect of tic severity (F(2,294) ¼ 5.44; P ¼ 0.005)
and CpG position (F(1,294) ¼ 26.45; P < 0.001): Mean methylation
was lower in patients suffering from more severe tics (see Fig. 3).Fig. 1. Methylation of the dopamine D2 receptor (DRD2) gene: patients with Gilles de
la Tourette syndrome (TS) compared to healthy controls (HC).
Fig. 2. Methylation of the dopamine D2 receptor (DRD2) gene in patients with Gilles
de la Tourette syndrome (TS) depending on tic severity (according to YGTSS-TTS: “mild
TS”14, “moderate TS” ¼ 15e34, “severe TS”>35; patients with severe tics showed a
signiﬁcant hypermethylation (P-value given in the ﬁgure is derived from Bonferroni-
corrected all pairwise comparison of estimated marginal means stemming from the
mixed linear model analysis).
K.R. Müller-Vahl et al. / Journal of Psychiatric Research 86 (2017) 1e8 53.2.3. COMT gene
Only minimal variation in the promoter methylation of the
COMT gene was detected in our study. No single CpG reached the
quality control level of inter-individual variance >1%. Even if po-
tential statistical differences could be detected, we decided not to
proceed with the analysis as those potential differences would lack
biological relevance.4. Discussion
This is the ﬁrst study investigating DNA methylation of three
different dopaminergic genes (DRD2, DAT, and COMT) in a well
characterized group of adult patients with TS. The main ﬁndings of
this study are that methylation levels of the DRD2 gene were
elevated in patients with TS compared to normal controls. InFig. 3. Methylation of the dopamine transporter (DAT) gene in patients with Gilles de
la Tourette syndrome (TS) depending on tic severity (according to YGTSS-TTS: “mild
TS”14, “moderate TS” ¼ 15e34, “severe TS”35; horizontal line indicates mean
methylation level of DAT in healthy controls (n ¼ 51); P-values given in the ﬁgure are
derived from Bonferroni-corrected all pairwise comparison of estimated marginal
means stemming from the mixed linear model analysis).addition, we found an association between DNA methylation and
tic severity with higher methylation of DRD2, but lower methyl-
ation of DAT inmore severely affected patients. Wewere not able to
produce any meaningful results for COMT promoter methylation as
inter-individual variation at single CpGs was way below biological
relevance. Our results, therefore, not only corroborate available
data suggesting the “dopaminergic hypothesis” of TS, but in addi-
tion provide for the ﬁrst time direct evidence for an involvement of
DNA methylation of different dopaminergic genes in the patho-
genesis of TS.
Since dopamine plays a crucial role in the control of movements,
for many years a “dopaminergic hypothesis” has been suggested in
TS. This hypothesis is supported not only by ﬁndings from neuro-
imaging, postmortem and laboratory studies, but also by the well-
known beneﬁcial effects of dopamine blocking agents in tics (for
review see Singer, 2013). However, until today neither an associa-
tion between a candidate gene of the dopaminergic system could
be detected, nor the precise neuroanatomical and neurochemical
abnormality within the CSTC circuits. Assuming an involvement of
the dopaminergic system in the pathogenesis of TS, therefore, one
might speculate that the expression of dopaminergic genes might
be affected not by alterations in the DNA sequences, but epigenetic
modiﬁcations of these genes. In line with the hypothesis of a
complex interaction between genetic and epigenetic factors, it can
be assumed that altered methylation levels may be induced by
environmental factors resulting in altered gene functions.
In this study, we were able to demonstrate for the ﬁrst time
signiﬁcant differences in the frequency of site-speciﬁc cytosine
methylation modiﬁcation of DRD2 and DAT, but not COMT in pa-
tients with TS. With respect to the DRD2 gene, we found not only a
signiﬁcant difference in the methylation levels between patients
and controls, but also an association with tic severity suggesting
that DRD2 hypermethylation is related to the underlying cause of
TS. However, it has to be taken into account that we investigated a
group of adult patients and, therefore, secondary (compensatory)
mechanisms cannot entirely be excluded. In addition and in line
with results in other patients' groups, we found that methylation
increases with age (Abdolmaleky et al., 2004) and is inﬂuenced by
antipsychotic medication (Boyadjieva and Varadinova, 2012;
Castellani et al., 2015). Hence, it cannot be excluded that our re-
sults e at least in part e are inﬂuenced by these factors. However,
the ﬁnding of an association between methylation levels and tic
severity and the inclusion of an age-matched control group,
respectively, strongly suggests that detected altered epigenetic
regulation cannot simply be explained by the inﬂuence of anti-
psychotic medication and age, respectively.
It is well-known that the DRD2 plays a key role in neuro-
psychiatric symptoms. The receptor density is thought to inﬂu-
ence both the disease risk and pharmacological response (Gluskin
and Mickey, 2016). The DRD2 gene encodes a G protein-coupled
receptor that is located on dopaminergic neurons. Although
candidate gene association studies in TS failed to demonstrate that
the DRD2 gene is associated with TS, histological studies provided
evidence for increased DRD2 receptor density in frontal cortex and
striatum (Minzer et al., 2004; Yoon et al., 2007a). In general, it is
thought that the extent of DNA methylation correlates with the
extent of gene inactivation. Thus, it can be expected that increased
methylation in dopamine pathway genes inﬂuences transcription
and suppresses the functional gene products (Abdolmaleky et al.,
2004). Accordingly, it can be assumed that DRD2 hyper-
methylation - as demonstrated in this study - leads to dopami-
nergic dysfunction (Yuan et al., 2015). It is well known that reduced
activation of DRD2 receptors within the indirect striatal output
pathway results in enhanced thalamo-cortical movement-stimu-
lating activity (Harris and Singer, 2006). The family of D2-like
K.R. Müller-Vahl et al. / Journal of Psychiatric Research 86 (2017) 1e86receptors also includes dopamine autoreceptors. Dopamine autor-
eceptors regulate axonal and somatodendritic dopamine release,
dopamine neuron ﬁring rate, and dopamine synthesis. Thus, DRD2
hypermethylation might inﬂuence all these functions. Striatal
dopamine receptors including the DRD2 are primarily extra-
synaptic. Therefore, it is believed that tonic (extrasynaptic) dopa-
mine is regulated by presynaptic D2 and D3 autoreceptors (Rice
et al., 2011). Accordingly, it can be hypothesized that DRD2
hypermethylation inﬂuences tonic dopamine neuron activity and
consecutively causes altered dopamine-regulated striatal signaling
resulting in tics.
Our ﬁnding of a negative association between DAT methylation
and tic severity further supports the “dopaminergic hypothesis” of
TS. However, this result can be interpreted in different ways. On the
one hand, one might speculate that hypomethylation of the DAT
gene represents a secondary mechanism due to hypermethylation
of the DRD2 gene. It can be assumed that reduced DAT methylation
results in an overactive DAT system. Accordingly, increased DAT
binding has been found in TS suggesting a dopaminergic hyperin-
nervation in the striatum (Malison et al., 1995; Müller-Vahl et al.,
2000; Serra-Mestres et al., 2004). An overactive DAT system in
turn may lead to a lower extrasynaptic tonic (homeostatic) dopa-
mine level (Singer, 2013). In line with this hypothesis, in animal
studies, it has been proposed that increased DAT activity reﬂects a
compensatory mechanism to normalize extracellular dopamine
levels, when synaptic dopamine levels are high (Ferris et al., 2014).
Thus, it can be hypothesized that hypomethylation of the DAT gene
represents a consequence in order to compensate for increased
dopaminergic signal transduction due to DRD2 hypermethylation.
However, it is believed that changes in tonic dopamine trans-
mission dependent on tonic ﬁring of dopamine neurons, rather
than DAT activity (Grace, 1995). Therefore, on the other hand, it can
also be speculated that hypomethylation of the DAT gene is related
to the neurobiology of TS. It could be demonstrated that DAT in-
hibition also inﬂuences phasic dopamine signals (Zhang et al.,
2009). In line with this result, it has been demonstrated that the
functional efﬁcacy of DAT in regulating dopamine release decreases
as the ﬁring frequency increases (Benoit-Marand et al., 2001).
Accordingly, it has been suggested that abnormality of DAT results
in a hyperresponsive phasic dopaminergic system leading to an
altered afferent cortical input (Singer, 2013). An involvement of DAT
in the neurobiology of TS is further supported by the ﬁnding of a
signiﬁcant association between TS and the presence of a DAT1 DdeI
polymorphism (Yoon et al., 2007b). Comparably to DRD2 methyl-
ation we found a strong inﬂuence of age on DAT methylation.
Assuming an alteration of the tonic-phasic dopaminergic
signaling in TS, it is important to note that the regulation of this
release system seems to be a dynamic process (Rice et al., 2011).
Therefore, it is possible that the typical waxing and waning course
of tics is related to alternating (phasic and/or tonic) dopamine
levels. During recent years, several studies provided evidence for a
causal relationship between epigenetic alterations and psychiatric
disorders, particularly thosewith an episodic course such as bipolar
disorder and major depression (Pe~na et al., 2014; Tsankova et al.,
2007), since it is well-known that DNA methylation is a highly
dynamic process (Gilsbach et al., 2014). Against this background, it
can be hypothesized that in TS waxing and waning of tics may be
caused by dynamic changes of methylation levels of dopaminergic
genes inﬂuencing the tonic/phasic dopaminergic signaling in the
striatum and thalamo-cortical output pathways.
With respect to COMTmethylationwe failed to demonstrate any
meaningful differences between patients and controls or an asso-
ciation with tic severity. Interestingly, neither sex, nor kind or
number of comorbidities, nor treatment with antidepressants or
DBS had an inﬂuence on the methylation status of DRD2, DAT, andCOMT genes. The lack of an association between psychiatric
comorbidities such as OCD, ADHD, and depression andmethylation
levels further supports the hypothesis that methylation status of
DRD2 and DAT directly inﬂuence tic severity.
The following limitations of the study have to be addressed: (i)
We included a relatively small number of patients (n ¼ 51); (ii) We
did not investigate an association between methylation levels and
age of tic-onset; (iii) Sincewe investigated a group of adult patients,
secondary mechanisms cannot be excluded. Therefore, it would be
of interest to investigate the methylation status of dopaminergic
genes in children at early stages of the disease; (iv) Since this was a
cross-sectional study, we did not investigate intra-individual vari-
ations of methylation levels in relation to spontaneous tic ﬂuctua-
tions. However, a follow-up study in the same group of patients is
in preparation in order to investigate whether waxing and waning
of tics is indeed linked to DNAmethylation; (v) Since this is the ﬁrst
study reporting about altered methylation of speciﬁc dopaminergic
pathway genes in TS, our data needs to be replicated in an inde-
pendent sample including a larger group of unmedicated patients;
(vi) Finally, all measurements were performed using DNA isolated
from blood, which does not necessarily need to reﬂect central
nervous processes. However, only recently we were able to
demonstrate an association not only between methylation of DAT
in blood cells and amygdala activation in patients with alcohol
dependence (Wiers et al., 2015), but also between DRD2 methyl-
ation in mucosal cells and pathological gambling behavior and
impulsivity (Hillemacher et al., 2015). In a rat model of schizo-
phrenia we observed a correlation between DRD2 methylation in
blood and cerebral tissue (Rhein et al., 2013). These ﬁndings,
therefore, strongly argue for a direct cross-talk between peripheral
and central epigenetic regulation of dopaminergic genes.
In conclusion, our results provide evidence for a role of altered
epigenetic regulation of dopaminergic genes in the pathophysi-
ology of TS. In line with the hypothesis of an interaction between
genetic and environmental factors in TS, it can be assumed that
environmental factors may cause epigenetic changes of dopami-
nergic genes resulting in altered gene functions. While DRD2
hypermethylation seems to be directly related to the neurobiology
of TS that may lead to dopaminergic dysfunction resulting in
enhanced thalamo-cortical movement-stimulating activity, DAT
hypomethylation might reﬂect a secondary mechanism in order to
compensate for increased dopaminergic signal transduction due to
DRD2 hypermethylation. In addition, it can be speculated that
spontaneous ﬂuctuations of tics may be caused by short-term al-
terations of methylation levels of dopaminergic genes resulting in
dynamic changes of tonic/phasic dopaminergic signaling in the
striatum and thalamo-cortical output pathways.
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